ALPHAMAB ONCOLO.DL-000002
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors… Read more
ALPHAMAB ONCOLO.DL-000002 (3NK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ALPHAMAB ONCOLO.DL-000002 (3NK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ALPHAMAB ONCOLO.DL-000002 - Net Assets Trend (None–None)
This chart illustrates how ALPHAMAB ONCOLO.DL-000002's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ALPHAMAB ONCOLO.DL-000002 (None–None)
The table below shows the annual net assets of ALPHAMAB ONCOLO.DL-000002 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ALPHAMAB ONCOLO.DL-000002's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ALPHAMAB ONCOLO.DL-000002 Competitors by Market Cap
The table below lists competitors of ALPHAMAB ONCOLO.DL-000002 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PBIIF
PINK:PBIIF
|
$485.28 Million |
|
Xianhe Co Ltd
SHG:603733
|
$485.33 Million |
|
Chengdu B-ray Media Co Ltd
SHG:600880
|
$485.37 Million |
|
Vesuvius India Limited
NSE:VESUVIUS
|
$485.40 Million |
|
Consensus Cloud Solutions Inc
NASDAQ:CCSI
|
$485.21 Million |
|
Shenzhen Liantronics
SHE:300269
|
$485.16 Million |
|
Lanzhou Haimo Technologies Co
SHE:300084
|
$485.03 Million |
|
Gifore Agricultural Machinery Chain Co Ltd
SHE:300022
|
$484.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ALPHAMAB ONCOLO.DL-000002's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ALPHAMAB ONCOLO.DL-000002's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ALPHAMAB ONCOLO.DL-000002 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ALPHAMAB ONCOLO.DL-000002's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ALPHAMAB ONCOLO.DL-000002 (3NK) | €- | N/A | N/A | $485.28 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |